Cite
HARVARD Citation
Nieto, Y. et al. (2017). High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet. 4 (6), pp. e283-e292. [Online].